• TROLL-8 mRNA: What the Evidence Supports

  2026-10-15

  The available product listing identifies TROLL-8 mRNA, SKU R1999, as an APExBIO product presented as an mRNA material. It provides no product description and has no identity-matched research study, so it supports catalog-level identification only; the encoded sequence, molecular mechanism, measured performance, and applicability remain unestablished.

• AS1842856: Evidence-Bounded Foxo1 Overview

  2026-10-15

  APExBIO describes AS1842856 as a small-molecule Foxo1 inhibitor that acts through direct binding rather than reducing Foxo1 expression. Its product-page claims connect Foxo1 activity to promoter regulation, gluconeogenic gene expression, glucose production, autophagy, and blood-glucose readouts. Because no identity-matched research paper is available here, these findings should be treated as supplier-reported evidence rather than independently verified efficacy. The main interpretive boundary is the distinction between target-level activity, downstream molecular measurements, and organism-level metabolic outcomes.

• Sulfo-Cy5 Carboxylic Acid: Scope and Evidence

  2026-10-14

  Sulfo-Cy5 carboxylic acid is described by APExBIO as a non-activated, sulfonated fluorescent dye with red/far-red optical properties and high aqueous solubility. Its documented value is as a fluorescence reporter, but the available evidence is product-level rather than identity-matched study evidence; fluorescence signal alone cannot establish biological activity, target engagement, or imaging performance in a particular system.

• GDC-0941 and DRD4–PI3K/Akt Evidence

  2026-10-14

  The 2024 liver-cancer study links DRD4 with cancer stem cell-like traits through PI3K/Akt/GSK-3β signaling, while supplier information describes GDC-0941 as a class I PI3K inhibitor. These sources support a mechanistic rationale for studying pathway dependence, but they do not establish that GDC-0941 selectively targets DRD4-driven liver cancer or reverses clinical chemoresistance.

• Bay 11-7821 in Context: What the Evidence Shows

  2026-10-13

  The supplied sepsis study implicates lactate-associated signaling in macrophage HMGB1 modification and release, but it does not test Bay 11-7821 (BAY 11-7082). The compound’s reported NF-κB and apoptosis-related activities therefore provide context for inflammatory signaling pathway research, not evidence that it regulates the lactate–HMGB1 mechanism described here.

• How SARS-CoV-2 PLpro Alters ER Proteins

  2026-10-13

  A 2023 Journal of Biological Chemistry study examined whether ER-localized SARS-CoV-2 papain-like protease (PLpro) regulates candidate ER-associated degradation substrates involved in lipid biosynthesis. The reported results support a dual model in which membrane-anchored PLpro can both reduce ubiquitination and cleave selected cellular proteins, although the findings were generated in a coexpression-based system and do not by themselves establish effects during infection or in patients.

• HyperPFU: Evidence, Scope and Applicability

  2026-10-12

  HyperPFU™ is described by APExBIO as a proofreading DNA polymerase for accurate amplification of difficult templates, while the supplied Zellweger spectrum disorder study evaluates base editing as a therapeutic strategy. These technologies address different scientific questions: one supports nucleic-acid analysis, whereas the other seeks to correct a disease-associated allele in biological systems. The available evidence supports conceptual distinctions, not direct claims that the polymerase improves or enables the reported therapeutic findings.

• G007-LK, Tankyrase, and YAP in Liver Cancer

  2026-10-12

  A source-grounded overview of Jia et al. (2017), which examined how the tankyrase inhibitors G007-LK and XAV-939 affect hepatocellular carcinoma cell growth and whether Hippo–YAP signaling helps explain those effects.

• Phosphorylation Evidence Gaps in Stroke Research

  2026-10-11

  The supplied mouse study supports a CKLF1-associated inflammatory mechanism for esculetin, but it does not compare phosphatase-inhibitor systems or establish that preserved phosphorylation measurements explain the reported outcomes.

• A-1210477 and the Logic of MCL-1 Dependence

  2026-10-10

  A-1210477 offers a selective way to examine MCL-1-dependent cancer cell survival and mitochondrial apoptosis. This evidence-focused analysis distinguishes chemical sensitivity from causal dependence, clarifies the significance of BAX/BAK biology, and defines the limits of translating in vitro findings.

• TaqI Restriction Endonuclease: Product Overview

  2026-10-09

  TaqI restriction endonuclease (SKU K3053) is an APExBIO-listed molecular biology enzyme described for sequence-specific DNA cleavage. No matched paper evidence is available, so the overview is limited to documented product information and does not establish independent performance.

• Pexmetinib (ARRY-614): Evidence and Limits

  2026-10-09

  Pexmetinib, also called ARRY-614, is described as a dual p38 MAPK and Tie2 inhibitor with reported activity in cytokine-related assays. The available evidence supports mechanistic and translational research use, but it does not establish clinical efficacy or prove that ARRY-614 shares every dephosphorylation effect reported for other p38α inhibitors.

• Okadaic Acid A4540: Product Overview

  2026-10-08

  Okadaic acid (SKU A4540) is documented by APExBIO as a marine-derived inhibitor of PP1 and PP2A. No matched paper evidence is available, so this overview is limited to product identity, stated target scope, and applicability boundaries.

• SIRT1, Type H Vessels, and Aging Bone Repair

  2026-10-08

  Liu et al. connect declining SIRT1 activity with impaired endothelial and osteogenic function in aged bone, then link SIRT1 activity to β-catenin deacetylation, nuclear localization, and Wnt signaling. Their combined in vitro and in vivo evidence supports SIRT1 as a mechanistically relevant regulator of vascular–osteogenic coupling, while leaving important questions about model specificity and therapeutic translation.

• MCL-1 Dependence in Breast Cancer: Study Insights

  2026-10-07

  Campbell et al. show that established breast tumours depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK, rather than because of a separable non-apoptotic function. The study links genetic loss and pharmacological inhibition of MCL-1 to tumour control while defining the evidence boundaries relevant to MCL-1-focused cancer research.

8149 records 1/544 page Next 12345 下5页 Last page